[Lyell's syndrome: proposal for a therapeutic protocol]

Area of Science:

• Dermatology
• Immunology
• Critical Care Medicine

Context:

• Toxic epidermal necrolysis (TEN), also known as Lyell's syndrome, is a severe, life-threatening mucocutaneous reaction.
• Drug-induced hypersensitivity reactions are the primary cause of TEN, necessitating urgent and effective treatment strategies.
• Current treatment paradigms for TEN often involve corticosteroids, but patient response can be variable, especially in severe cases.

Purpose:

• To evaluate the safety and efficacy of plasmapheresis as a potential first-line treatment for toxic epidermal necrolysis.
• To assess the utility of plasmapheresis in patients with TEN who exhibit resistance to corticosteroid therapy.
• To determine the impact of plasmapheresis on pain relief and the cessation of necrolysis in TEN patients.

Summary:

• Plasmapheresis, despite its cost and requirement for venous access, demonstrates significant potential as a first-line therapy for TEN.
• The procedure was observed to be safe and effective, leading to prompt pain reduction and rapid halting of epidermal necrolysis.
• Notably, plasmapheresis proved beneficial for patients refractory to corticosteroids and those presenting with severe clinical manifestations of TEN.

Impact:

• Plasmapheresis may represent a valuable therapeutic option for managing severe cases of toxic epidermal necrolysis.
• This approach could improve patient outcomes by providing rapid symptom control and potentially reducing treatment-related morbidity.
• Further research into the integration of plasmapheresis into established TEN treatment protocols is warranted.